Disease, Wellness and Longevity Claims: The US Evidence and Scope Boundary

The useful distinction is not between sophisticated and unsophisticated longevity language. It is between what an audience is led to believe and what the evidence supports. This article concerns selected US FDA and FTC frameworks. It does not decide the legality of an individual product, clinic or advertisement. Sources: FDA: Small entity compliance guide—structure/function claims; FTC: Health Products Compliance Guidance.

Structure/function is a category-specific framework

FDA’s dietary-supplement guidance distinguishes structure/function claims from disease claims and describes substantiation, disclaimer and notification conditions. It is not a general authorization for every product carrying a wellness label. Disease-risk-reduction health claims also have their own framework, so “prevention” should not be treated as one universal legal category. Sources: FDA: Small entity compliance guide—structure/function claims.

A phrase such as “supports muscle function” is not a preapproved safe harbor. Its truthfulness, context and implied meaning still matter. Replacing a disease name with “optimization” does not establish that a claim is substantiated or that the product falls within a particular regulatory category. Sources: FDA: Small entity compliance guide—structure/function claims; FTC: Health Products Compliance Guidance.

Advertising is about the whole impression

FDA is not the only regulator in the room. The FTC’s Health Products Compliance Guidance is a useful reminder that advertising claims need competent and reliable scientific evidence. A longevity company can avoid the most obvious disease words and still be in trouble if the overall advertising impression promises more than the evidence supports. Implied claims count. Visuals count. Testimonials count. Before-and-after biomarker narratives can count. Sources: FTC: Health Products Compliance Guidance.

That is a practical trap for claims built around dashboards and biological-age numbers. If a brand shows a customer that a clock moved backward after a protocol, then uses that story to suggest reduced dementia risk, cancer prevention or cardiovascular protection, the claim has grown beyond the measurement. A biomarker movement is not automatically a clinical outcome. The example illustrates an inference boundary; it does not establish how frequently companies cross it. Sources: FTC: Health Products Compliance Guidance; FDA facts: biomarkers and surrogate endpoints.

FTC’s health-products guidance addresses express and implied advertising claims and the evidence needed to substantiate them. A disclaimer should not be used to contradict the main promise. A study of an ingredient, animal mechanism or surrogate marker must not be presented as though it demonstrated the advertised product’s clinical outcome. Sources: FTC: Health Products Compliance Guidance.

Prevention, optimization and treatment are not three evidence grades

These words describe different intentions but do not, by themselves, determine the applicable legal route. Prevention can describe an established clinical outcome, a disease-risk claim or a vague promotional aspiration. Optimization names no specific endpoint. Treatment likewise requires the actual product and intended use to be identified. The evidence question is what outcome the claim communicates. Sources: FDA: Small entity compliance guide—structure/function claims; FTC: Health Products Compliance Guidance.

Wellness optimization should not be treated as a category that generally needs only modest substantiation. A less explicit word can still imply a strong health benefit. Evidence should match the claim’s meaning, not the advertiser’s preferred category label. Sources: FTC: Health Products Compliance Guidance.

The low-risk device policy has boundaries

FDA’s January 2026 general-wellness guidance concerns low-risk devices. Its scope does not extend the same policy to drugs, biologics, dietary supplements, foods, cosmetics or combination products. It should not be cited as a universal longevity-business exemption. Sources: FDA: General Wellness—Policy for Low Risk Devices.

Sources: FDA: Small entity compliance guide—structure/function claims; FTC: Health Products Compliance Guidance; FDA: General Wellness—Policy for Low Risk Devices.

Clinics and diagnostics require additional questions

A service delivered by a clinic is not a supplement label. Facility, professional, testing, advertising and research obligations may depend on the activity and jurisdiction. This article does not establish permission to offer any procedure. The clinic-evaluation framework instead asks for governance, evidence, consent, adverse-event handling and transparent outcomes. Sources: FDA: General Wellness—Policy for Low Risk Devices; FTC: Health Products Compliance Guidance.

For a diagnostic claim, distinguish measuring a signal, predicting an outcome and improving a decision. A numerical biological-age result does not itself establish clinical utility. Adding a physician’s interpretation does not replace the need to substantiate the underlying claim. Sources: FDA facts: biomarkers and surrogate endpoints; Validation of biomarkers of aging..

Claim discipline is not a market forecast

The compliance answer is not to stop talking about longevity. It is to make the claim architecture cleaner. Brands need to separate wellness-support claims from disease claims, customer education from medical advice, biomarker movement from clinical outcomes, and hypothesis from validated utility. They also need substantiation that matches the strength of the claim. A cautious claim backed by relevant evidence is stronger than a dramatic claim held together by citations from adjacent biology. Sources: FTC: Health Products Compliance Guidance; FDA: Small entity compliance guide—structure/function claims.

That is an editorial credibility standard, not a prediction about which brands will survive. This record offers no provider endorsement, legal opinion or patient-specific selection advice. Professional review of a real claim must examine its complete context and current controlling rules. Sources: FTC: Health Products Compliance Guidance.

Update triggers

Reassess after a relevant final guidance, regulatory or court decision, a material change to the product or claim, or new evidence that changes the supported outcome. The date of a cited study is not a substitute for checking the current scope of the applicable framework. Sources: FDA: Small entity compliance guide—structure/function claims; FDA: General Wellness—Policy for Low Risk Devices; FTC: Health Products Compliance Guidance.

Related intelligence

Evidence-Based Longevity Clinics: A Framework for Evaluating Services, Claims, and Transparency; What an Aging-Drug Claim Must Define: A US Regulatory Evidence Framework; Aging Biomarkers Compared: What Each Measure Captures—and What It Cannot Prove.